Tag: Atricure

AtriCure Reports Second Quarter 2018 Financial Results

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2018 financial results. “Our second quarter results reflect strong revenue growth, solid operational performance and continued execution on our strategic priorities,” said Mike Carrel, President and Chief […]

AtriCure and Baheal Group Establish Partnership and China Distribution Agreement

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has partnered with Baheal Pharmaceutical Group in China to distribute AtriCure’s surgical ablation devices. This new multi-year agreement establishes Baheal as the exclusive distributor for AtriCure, and replaces the […]

AtriCure Reports First Quarter 2018 Financial Results

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced first quarter 2018 financial results. “We are pleased with our first quarter performance and meaningful progress toward completing enrollment in CONVERGE,” said Mike Carrel, President and Chief Executive Officer […]

AtriCure Announces U.S. Launch of the AtriClip® PRO•V™ Device

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has launched the AtriClip PRO•V™ Left Atrial Appendage (LAA) Exclusion System in the United States. The new device offers an open-ended design combined with a tip-first closure […]

AtriCure (ATRC) Reports Second Quarter 2017 Financial Results

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2017 financial results. “We are executing on our strategy to deliver solid, balanced, results across our business while progressing forward our clinical trials and strategic initiatives,” […]

AtriCure (ATRC) Announces Hiring Of Chief Technology Officer

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has hired Salvatore (Sam) Privitera as its Chief Technology Officer. Mr. Privitera will have responsibility for Research and Development activities, as well as Operations, including manufacturing, […]

AtriCure (ATRC)’s AtriClip System Surpasses 100,000 Units Sold Worldwide

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has sold more than 100,000 AtriClip® Left Atrial Appendage Exclusion System devices worldwide, which makes it the most widely used of all devices for excluding the […]

AtriCure Names National Principal Investigator for the CONVERGE IDE Clinical Trial

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has named Dr. David B. DeLurgio as the national principal investigator (PI) for the CONVERGE IDE clinical trial. “I am honored and humbled to be […]